Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration, FDA, has granted Rare Pediatric Disease, RPD, Designation for the Company’s lead asset, QRX003, for the treatment of Netherton Syndrome. The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population. It follows earlier regulatory recognition by the European Medicines Agency, EMA, which granted Orphan Drug Designation to QRX003 in May 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNRX:
- Quoin Pharmaceuticals Updates Shareholder Proposal Deadlines
- Quoin Pharmaceuticals Approves Executive Cash Bonuses
- Quoin Pharmaceuticals Receives FDA Clearance for New Study
- Quoin announces FDA clearance to initiate second whole body QRX003 NS study
- Quoin Pharmaceuticals’ QRX003 Gains Orphan Drug Status